Listen to this informative panel discussion about the use of site specific immunomodulators (SSIs), an investigational treatment aimed at stimulating the immune system to reverse the chronic inflammation underlying Crohn’s disease. Panel includes: Gastroenterologist Dr. Brian Bressler, Principal Investigator of Qu Crohn’s Trial Qu Biologics’ founder and CEO, Dr. Hal Gunn Qu Biologics’ Chief Medical […]

Update December 10th – Podcast of the show now available. Listen here. ______ Tune into The Natural Health Show this weekend for a special report on the impact of Crohn’s disease. Host Steve Herringer will interview Qu Crohn’s Trial Principal Investigator, Dr. Brian Bressler and Qu Biologics CEO, Dr. Hal Gunn. This segment will also feature […]

Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced that it has received ethics approval to implement a program to help subsidize travel and hotel costs for participants of its Crohn’s disease clinical trial. “In response to participant interest from across Canada we felt […]

Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s immune system, announced it has enrolled its first patient in a Phase 1/2 clinical trial of QBECO SSI for the treatment of Crohn’s disease. The company recently launched the Crohn’s disease clinical trial and is actively recruiting participants with moderate-to severe Crohn’s disease

Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to “reboot” the body’s innate immune system, is pleased to welcome internationally recognized gastroenterology experts Dr. Richard Fedorak and Dr. William Sandborn to the company’s newly formed Inflammatory Bowel Disease (IBD) advisory team. Qu Biologics has developed the IBD advisory team to provide guidance and independent oversight of its new Phase 1/2 clinical trial of its investigational drug, QBECO Site Specific Immunomodulator (SSI) for Crohn’s disease. The company launched the Crohn’s disease clinical trial in March and is actively recruiting participants with moderate-to severe Crohn’s disease for this trial.

Canadian participants are being sought for a new Health Canada-approved clinical trial for the treatment of Crohn’s disease, the Vancouver-based biopharmaceutical company Qu Biologics announced today.

Affecting more than 100,000 Canadians, Crohn’s disease is a type of inflammatory bowel disease that causes a range of debilitating symptoms including abdominal pain, diarrhea, vomiting and weight loss. Crohn’s disease is one of a number of autoimmune diseases and cancers that are marked by chronic inflammation within a specific organ or tissue.